The first breakthrough in the RECOVERY trial came within three months – the finding that the cheap steroid dexamethasone saves the lives of hospitalised patients. The trial continues to investigate a range of treatments, and recently launched RECOVERY International, to evaluate COVID-19 therapies that may be suitable for low-resource countries. ‘The RECOVERY trial is, quite simply, an extraordinary endeavour,' says Professor Martin Landray. It really has put randomised trials at the heart of high-quality healthcare – for COVID-19 and beyond.’‘Being given the opportunity to participate in the RECOVERY trial was very humbling, knowing that the information they were collecting had a direct impact on the treatment of patients, and signing on was something I did gladly,' says Kimberley Featherstone, RECOVERY trial participant. To find out more about the extraordinary work of the RECOVERY trial, there will be a special webinar to mark the one-year anniversary of the trial on 7 April 2021.
